The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.

The following is a summary of “Feasibility of trancutaneous auricular vagus nerve stimulation in Black and Hispanic/Latino people with peripheral neuropathy,” published in the January 2025 issue of ...

The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

The following is a summary of “Correlation between high-sensitivity cardiac troponin levels in diabetic patients’ serum and ...

In recent weeks, reports have been circulating about severe reactions in people who've taken over-the-counter vitamin B6 supplements.

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid medication for treating moderate to severe acute pain in adults. Journavx, approved ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...

SLEEP is essential for good health and well-being. It keeps heart health in check, helps you maintain a healthy weight, makes ...